![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Impact of Hepatitis C Treatment With Glecaprevir + Pibrentasvir on Patient's Health Related Quality of Life: Results From Phase 3 CERTAIN Trials
|
|
|
Reported by Jules Levin
AASLD - American Association for The study of Liver Diseases (AASLD) ° October 20 - 24, 2017 ° Washington DC, USA
Hiromitsu Kumada,1 Kazuaki Chayama,2 Darshan Mehta,3,4 Brett Pinsky4 1Toranomon Hospital, Kanagawa, Japan; 2Hiroshima University, Hiroshima, Japan; 3Schaeffer Center for Health Policy and Economics, University of Southern California, Mettawa, IL, United States; 4Health Economics and Outcomes Research, AbbVie Inc., Mettawa, IL, United States
![1027171](../images/102817/102817-2/1027171.gif)
![1027172](../images/102817/102817-2/1027172.gif)
![1027173](../images/102817/102817-2/1027173.gif)
![1027174](../images/102817/102817-2/1027174.gif)
![1027175](../images/102817/102817-2/1027175.gif)
![1027176](../images/102817/102817-2/1027176.gif)
![1027177](../images/102817/102817-2/1027177.gif)
![1027178](../images/102817/102817-2/1027178.gif)
![1027179](../images/102817/102817-2/1027179.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|